Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 8/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7385841 | 0.90 | CACNA1B (0.51) | CACNA1BMEN1KMT2AGPR119 | |
| SCHEMBL7040340 | 0.89 | CACNA1B (0.69) | CACNA1BMEN1KMT2A | |
| SCHEMBL7036969 | 0.85 | MEN1 (0.46) | CACNA1BMEN1KMT2AGPR119 | |
| SCHEMBL7038257 | 0.85 | CACNA1B (0.51) | CACNA1BMEN1KMT2AJAK2JAK1 | |
| SCHEMBL7043625 | 0.84 | CACNA1B (0.76) | CACNA1BMEN1KMT2A | |
| SCHEMBL7043621 | 0.84 | CACNA1B (0.76) | CACNA1BMEN1KMT2A | |
| SCHEMBL7388010 | 0.84 | NPC1 (0.54) | CACNA1BMEN1KMT2AGPR119 | |
| SCHEMBL7381620 | 0.82 | CACNA1B (0.57) | CACNA1BMEN1KMT2AJAK2JAK1 | |
| SCHEMBL7393443 | 0.82 | CACNA1B (0.51) | CACNA1BMEN1KMT2AGPR119 | |
| SCHEMBL7787549 | 0.81 | CACNA1B (0.51) | CACNA1BMEN1KMT2AJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030060632-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2003-03-27 | — | — | US | disclosed |
| US-6495715-B2 | STROKE, ANTIISCHEMIC AGENTS, TRAUMAS, ANTIEPILEPIC AGENTS | WARNER-LAMBERT COMPANY | 2002-12-17 | — | — | US | disclosed |
| US-20010023249-A1 | Calcium channel blockers | HU LAIN-YEN (US) | 2001-09-20 | — | — | US | disclosed |
| US-6251918-B1 | FOR THERAPY OF STROKE, CEREBRAL ISCHEMIA, HEAD TRAUMA, OR EPILEPSY | WARNER-LAMBERT COMPANY | 2001-06-26 | — | — | US | disclosed |
| US-6251919-B1 | ADMINISTERING ANILINE DERIVATIVE FOR THERAPY OF PAIN | WARNER-LAMBERT | 2001-06-26 | — | — | US | disclosed |
| WO-1999043658-A1 | HETEROCYCLIC SUBSTITUTED ANILINE CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999007689-A1 | ANILINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | WARNER-LAMBERT COMPANY (US) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010023249-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | CACNA1B 2/4885MEN1 829/4885KMT2A 4017/4885 |
| US-20030060632-A1 | Calcium channel blockers | CACNA1I, CACNA1B, CACNA1G | CACNA1B 2/4885MEN1 829/4885KMT2A 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.